In this trial, mean weight loss was comparable to that of individuals with obesity treated with semaglutide
Only seven patients (5%) experienced moderate effects, and no major effects or deaths were recorded
HM15275: Next-Generation Triple Agonist Targeting Quantity and Quality of Weight Loss HM15275 is engineered to optimize the activity balance of GLP-1, GIP, and glucagon (GCG) receptors, delivering targeted obesity treatment while also addressing comorbid metabolic conditions such as diabetes, cardiovascular, and renal disease
Hold the pen at a 90-degree angle to the skin and insert the needle fully into the chosen injection site
GLP-1 injections are administered subcutaneously, just under the skin, so the ideal areas have enough fatty tissue and are easy to reach
Ozempic is a diabetes medication that reduces blood sugar and is also prescribed for chronic weight management under related brand names, but recent studies and reported adverse events have raised questions about potential optic nerve complications in some patients